Cancer Drug Resistance

Show Articles
Journal Properties
  • Country
    United States
  • Language
    English
  • Number of Articles
    170
  • Abbreviation
    Cancer Drug Resist
  • e-ISSN
    2578-532X
  • Main Publisher
    OAE Publishing Inc.
  • Publisher
    OAE Publishing Inc.
  • Indian UGC
  • DOAJ (latest)
Journal Properties
  • Medicine
    Internal medicine
    Neoplasms
    Tumors
    Oncology
    Including cancer and carcinogens
Description
This journal is dedicated to exploring the multifaceted mechanisms of drug resistance in cancer and identifying strategies to overcome them. It serves as a platform for disseminating cutting-edge research on the molecular, cellular, and clinical aspects of cancer drug resistance. The journal covers a broad range of topics, including genetic and epigenetic alterations, signaling pathway dysregulation, tumor microenvironment interactions, and the development of novel therapeutic approaches to circumvent resistance. Cancer Drug Resistance also welcomes contributions on preclinical and clinical studies evaluating new drug combinations, targeted therapies, and immunotherapeutic strategies. The target audience includes researchers, clinicians, and pharmaceutical professionals dedicated to improving cancer treatment outcomes. Indexing databases include Web of Science. By fostering collaboration and knowledge sharing, Cancer Drug Resistance aims to accelerate the development of more effective cancer therapies and ultimately improve patient survival.